These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32107549)

  • 1. Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients.
    Barritault M; Picart T; Poncet D; Fenouil T; d'Hombres A; Gabut M; Guyotat J; Jouanneau E; Ameli R; Joubert B; Streichenberger N; Vasiljevic A; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2020 Sep; 87(4):E513-E519. PubMed ID: 32107549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
    Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
    J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human TERT promoter mutations as a prognostic biomarker in glioma.
    Powter B; Jeffreys SA; Sareen H; Cooper A; Brungs D; Po J; Roberts T; Koh ES; Scott KF; Sajinovic M; Vessey JY; de Souza P; Becker TM
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1007-1017. PubMed ID: 33547950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
    Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
    Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
    Killela PJ; Pirozzi CJ; Healy P; Reitman ZJ; Lipp E; Rasheed BA; Yang R; Diplas BH; Wang Z; Greer PK; Zhu H; Wang CY; Carpenter AB; Friedman H; Friedman AH; Keir ST; He J; He Y; McLendon RE; Herndon JE; Yan H; Bigner DD
    Oncotarget; 2014 Mar; 5(6):1515-25. PubMed ID: 24722048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
    Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
    BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Zhang Z; Chan AK; Ding X; Li Y; Zhang R; Chen L; Liu Y; Wang Y; Xiong J; Ng HK; Yao Y; Zhou L
    Neuro Oncol; 2017 Jul; 19(7):1008-1010. PubMed ID: 28874004
    [No Abstract]   [Full Text] [Related]  

  • 18.
    Barange M; Epari S; Gurav M; Shetty O; Sahay A; Shetty P; Goda J; Moyiadi A; Gupta T; Jalali R
    Neurol India; 2021; 69(1):126-134. PubMed ID: 33642283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Wefel JS; Noll KR; Rao G; Cahill DP
    Neuro Oncol; 2016 Dec; 18(12):1656-1663. PubMed ID: 27576872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.